Chemo infusion for liver cancer using a hybrid care model
Part of Cancer clinical trials.
This trial tests a special type of chemotherapy (hepatic artery infusion) for people with cancers that have spread to the liver, such as colorectal cancer or bile duct cancer (intrahepatic cholangiocarcinoma). It studies whether delivering this treatment partly at a community center and partly at a university hospital is safe and feasible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have colorectal cancer or bile duct cancer that has spread to the liver, with no cancer found outside the liver (except up to 5 stable lung spots or lymph nodes near the liver that can be removed).
- Your liver cancer cannot be removed by surgery (Group A or C) or can be completely removed (Group B).
- You are in good physical condition (able to perform daily activities with little or no help).
- Blood tests show adequate liver and kidney function, and enough blood cells (no severe anemia, infection, or bleeding problems).
- You can travel every 2 weeks for 6 months for treatment, either to Lexington, KY or to a local community site.
- If you have HIV, hepatitis B, or hepatitis C, you must be on effective treatment and have an undetectable viral load.
- You must not have had prior radiation to the liver or certain other cancers that could interfere with this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving extra chemotherapy directly to the liver through a small pump (called HAIP) before or after surgery can improve outcomes for patients with bile duct cancer inside the liver. It is for patients whose cancer is considered removable by surgery.
This trial tests a new combination of treatments for intrahepatic cholangiocarcinoma (a bile duct cancer in the liver) that cannot be surgically removed. It combines chemo directly into the liver with two drugs that boost the immune system and block blood vessel growth, hoping to shrink the tumor and help you live longer.
This trial tests a combination of drugs to treat advanced bile duct cancer that cannot be removed by surgery. The treatment may help shrink tumors and improve outcomes.
This trial tests whether adding a special chemotherapy pump implanted in your liver (hepatic arterial infusion) to standard chemotherapy works better than standard chemotherapy alone for people whose colorectal cancer has spread only to the liver and cannot be removed by surgery. The pump delivers high doses of chemo directly to the liver to shrink tumors and possibly control the disease longer.
This trial tests a combination of liver-directed treatments and immunotherapy with a targeted drug for people whose liver cancer has spread to a few other organs. It aims to shrink tumors and improve outcomes.
This trial tests a combination of two treatments—a targeted pill (donafenib) and an immunotherapy drug (pucotenlimab)—along with a type of chemotherapy given directly to the liver through a catheter. The goal is to see if this combination can shrink or control liver cancer better than standard options.
Hear when a new Intrahepatic Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.